|
Valoración de DCF de mesoblast limitado (meso)
AU | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Mesoblast Limited (MESO) Bundle
Ingementista para su precisión, nuestra calculadora DCF (meso) le permite evaluar la valoración de Mesoblast Limited utilizando datos financieros del mundo real, ofreciendo una flexibilidad completa para modificar todos los parámetros clave para las proyecciones mejoradas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.2 | 7.5 | 10.2 | 7.5 | 5.9 | 4.6 | 3.6 | 2.8 | 2.2 | 1.7 |
| Revenue Growth, % | 0 | -76.81 | 36.95 | -26.54 | -21.32 | -21.93 | -21.93 | -21.93 | -21.93 | -21.93 |
| EBITDA | -75.4 | -107.6 | -76.6 | -58.6 | -62.8 | -4.6 | -3.6 | -2.8 | -2.2 | -1.7 |
| EBITDA, % | -234.5 | -1443.17 | -749.91 | -780.56 | -1064.44 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 3.7 | 4.3 | 4.4 | 4.1 | 4.7 | 2.3 | 1.8 | 1.4 | 1.1 | .8 |
| Depreciation, % | 11.4 | 57.19 | 42.89 | 54.75 | 79.06 | 49.06 | 49.06 | 49.06 | 49.06 | 49.06 |
| EBIT | -79.1 | -111.9 | -81.0 | -62.7 | -67.5 | -4.6 | -3.6 | -2.8 | -2.2 | -1.7 |
| EBIT, % | -245.9 | -1500.36 | -792.8 | -835.32 | -1143.49 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 129.3 | 136.9 | 60.0 | 70.9 | 62.6 | 4.6 | 3.6 | 2.8 | 2.2 | 1.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.3 | 4.6 | 4.4 | 2.3 | 21.0 | 2.2 | 1.7 | 1.3 | 1.0 | .8 |
| Account Receivables, % | 4.11 | 61.56 | 43.12 | 30.34 | 355 | 47.83 | 47.83 | 47.83 | 47.83 | 47.83 |
| Inventories | -.3 | -.3 | .0 | -4.3 | .0 | -.6 | -.4 | -.3 | -.3 | -.2 |
| Inventories, % | -0.78368 | -3.38 | 0 | -57.65 | 0 | -12.36 | -12.36 | -12.36 | -12.36 | -12.36 |
| Accounts Payable | 25.0 | 19.6 | 23.1 | 20.1 | 7.1 | 4.4 | 3.4 | 2.7 | 2.1 | 1.6 |
| Accounts Payable, % | 77.66 | 262.85 | 226.02 | 268.56 | 119.79 | 95.53 | 95.53 | 95.53 | 95.53 | 95.53 |
| Capital Expenditure | -2.2 | -1.6 | -.2 | -.3 | -.3 | -.4 | -.3 | -.2 | -.2 | -.1 |
| Capital Expenditure, % | -6.98 | -22.09 | -2.27 | -4.19 | -4.59 | -8.02 | -8.02 | -8.02 | -8.02 | -8.02 |
| Tax Rate, % | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 | 0.21668 |
| EBITAT | -70.5 | -110.9 | -80.7 | -62.5 | -67.3 | -4.5 | -3.5 | -2.7 | -2.1 | -1.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -45.2 | -117.0 | -73.2 | -55.2 | -99.0 | 14.0 | -2.6 | -2.1 | -1.6 | -1.3 |
| WACC, % | 15.49 | 15.51 | 15.51 | 15.51 | 15.51 | 15.5 | 15.5 | 15.5 | 15.5 | 15.5 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 7.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -9 | |||||||||
| Present Terminal Value | -5 | |||||||||
| Enterprise Value | 3 | |||||||||
| Net Debt | 56 | |||||||||
| Equity Value | -54 | |||||||||
| Diluted Shares Outstanding, MM | 987 | |||||||||
| Equity Value Per Share | -0.05 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real MESO financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Mesoblast’s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Customizable Forecast Inputs: Adjust essential factors such as revenue projections, EBITDA margins, and capital investments.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other relevant metrics.
- High-Precision Accuracy: Leverages Mesoblast Limited's (MESO) actual financial data for credible valuation results.
- Simplified Scenario Analysis: Easily evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- 1. Open the Template: Download and open the Excel file containing Mesoblast Limited’s (MESO) preloaded data.
- 2. Edit Assumptions: Modify key inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV.
- 4. Test Scenarios: Evaluate multiple forecasts to explore various valuation outcomes.
- 5. Use with Confidence: Present professional valuation insights to enhance your decision-making.
Why Choose This Calculator for Mesoblast Limited (MESO)?
- Accurate Data: Utilize real Mesoblast financials for dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Pre-configured calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Easy-to-navigate design and clear instructions ensure accessibility for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Mesoblast Limited (MESO) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Mesoblast Limited (MESO).
- Consultants: Deliver professional valuation insights on Mesoblast Limited (MESO) to clients quickly and accurately.
- Business Owners: Understand how companies like Mesoblast Limited (MESO) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Mesoblast Limited (MESO).
What the Template Contains
- Historical Data: Includes Mesoblast Limited’s (MESO) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Mesoblast Limited’s (MESO) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Mesoblast Limited’s (MESO) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.